Healthcare >> Analyst Interviews >> April 5, 2010
Dr. Jonathan Aschoff, Ph.D., is a Senior Equity Analyst at Brean Murray, Carret & Co., LLC. Prior to joining the firm in 2003, he held positions as a Senior Biotechnology Analyst at Friedman, Billings, Ramsey & Co., Inc., and at what is now RBC. He also served as an Analyst at Sturza Institutional Research. Prior to Wall Street, Dr. Aschoff was a Research Technician at New England Medical Center. He earned a Ph.D. in molecular biology and microbiology, as well as a B.S. in biology from Tufts University. Profile
TWST: Let's start with Medivation (MDVN). Why did you have a "sell" rating on it when most analysts had it as a "buy"-rated stock?
Dr. Aschoff: I had absolutely no belief that the
